MaRS EXCITE is an innovation in health technology assessment (HTA) where industry, academia, and the health system collaborate to design and execute a robust evaluation program for innovative medical technologies with high disruptive potential that proactively satisfies regulatory and reimbursement decision-makers requirements. EXCITE compromises five Methodological Centres (MCs) across Ontario, Canada with demonstrated excellence in methodologies for designing and conducting complex, multi-centre trials and HTAs. The MCs develop the protocol collaboratively with industry and experts, and oversee the clinical trials, involving multiple participating sites. In an attempt to promote consistency in Quality Assurance (QA) amongst MCs and participating sites for EXCITE studies, EXCITE has developed SOPs, through the Clinical Trials Methodology Committee, that relate exclusively to the unique collaboration with the MCs. These were developed through an analysis of host institution SOPs and developing overarching SOPs that were either unique to the EXCITE QA program, or where deemed appropriate though lacking from some host institutions. This harmonization of SOPs across the five current EXCITE MCs has allowed EXCITE to address one of the main goals of clinical trial QA that is integrity of data. The second goal of clinical trial QA, patient safety, is achieved through the Safety Advisory committee, which sets safety standards that must be adhered to by the MCs evaluating the technologies. The committee reviews all protocols to ensure that patient safety issues are addressed,makes recommendations for protocol changes as necessary and may also mandate training requirements to ensure competency in utilization of any medical technology undergoing testing in the EXCITE program.   Therefore, MaRS EXCITE was able to deploy a collaborative platform to harmonize the QA processes across five independent academic methodological centres in order to conduct efficient and effective clinical trials that are used in evaluating disruptive medical technologies in an effort to optimize patient outcomes.